EVEROLIMUS (RAD001) AND THE MTOR PATHWAY IN LOW-GRADE GLIOMAS

被引：0
|
作者：
Clarke, Jennifer L. [1 ]
Chang, Susan [1 ]
Phillips, Joanna [1 ]
Molinaro, Annette [1 ]
Berger, Mitchel [1 ]
Nelson, Sarah [1 ]
Haas-Kogan, Daphne [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
NEURO-ONCOLOGY | 2014年 / 16卷
关键词：
D O I：
10.1093/neuonc/nou209.24
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] RAD001 (everolimus)
    Soria, J. C.
    ANNALS OF ONCOLOGY, 2008, 19 : 21 - 22
  • [2] Analysis of the mTOR signaling pathway versus proliferative response of tumor cells to the mTOR inhibitor RAD001 (everolimus)
    Breuleux, M.
    Zumstein-Mecker, S.
    O'Reilly, T.
    Natt, F.
    Maira, M.
    Lane, H.
    EJC SUPPLEMENTS, 2006, 4 (12): : 181 - 181
  • [3] Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
    Chiong, Edmund
    Lee, I-Ling
    Dadbin, Ali
    Sabichi, Anita L.
    Harris, Loleta
    Urbauer, Diana
    McConkey, David J.
    Dickstein, Rian J.
    Cheng, Tiewei
    Grossman, H. Barton
    CLINICAL CANCER RESEARCH, 2011, 17 (09) : 2863 - 2873
  • [4] EFFECTS OF MTOR INHIBITOR EVEROLIMUS (RAD001) ON BLADDER CANCER CELLS
    Chiong, Edmund
    Lee, I-Ling
    Dadbin, Ali
    Sabichi, Anita L.
    McConkey, David J.
    Grossman, H. Barton
    JOURNAL OF UROLOGY, 2009, 181 (04): : 406 - 406
  • [5] Role of the Novel mTOR Inhibitor RAD001 (Everolimus) in Anaplastic Thyroid Cancer
    Papewalis, C.
    Wuttke, M.
    Schinner, S.
    Willenberg, H. S.
    Baran, A. M.
    Scherbaum, W. A.
    Schott, M.
    HORMONE AND METABOLIC RESEARCH, 2009, 41 (10) : 752 - 756
  • [6] Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma
    Oudard, Stephane
    Medioni, Jacques
    Aylllon, Jorge
    Barrascourt, Eduardo
    Elaidi, Reza-Thierry
    Balcaceres, Jose
    Scotte, Florian
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 705 - 717
  • [7] Everolimus (RAD001) compassionate supplies programme
    Chambers, J. S.
    REGULATORY PEPTIDES, 2010, 164 (01) : 10 - 10
  • [8] The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts
    Diana Behrens
    Anne E. Lykkesfeldt
    Iduna Fichtner
    Targeted Oncology, 2007, 2 : 135 - 144
  • [9] The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts
    Behrens, Diana
    Lykkesfeldt, Anne E.
    Fichtner, Iduna
    TARGETED ONCOLOGY, 2007, 2 (03) : 135 - 144
  • [10] A PROSPECTIVE MULTI-INSTITUTIONAL PHASE II STUDY OF EVEROLIMUS (RAD001), AN MTOR INHIBITOR, IN PEDIATRIC PATIENTS WITH RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA. A POETIC CONSORTIUM TRIAL
    Kieran, M.
    Yao, X.
    Macy, M.
    Geyer, R.
    Cohen, K.
    MacDonald, T.
    Allen, J.
    Boklan, J.
    Smith, A.
    Nazemi, K.
    Gore, L.
    Trippett, T.
    DiRenzo, J.
    Narendran, A.
    Perentesis, J.
    Prabhu, S.
    Pinches, N.
    Robison, N.
    Manley, P.
    Chi, S.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 19 - 20
12345